Rubin Eyal
SEC insider (Form 3/4/5 filer). CIK 0001721411. Chief Financial Officer at Nasus Pharma Ltd (NSRX) and 1 other issuer. 2 reported Form 4/5 transactions since Sep 2024; latest on Sep 23, 2024. Located in TEL-AVIV-YAFO.
Companies Rubin Eyal has filed insider reports for
- Nasus Pharma Ltd (NSRX): Officer, Chief Financial Officer
- Protalix BioTherapeutics, Inc. (PLX): Officer, Sr. VP and CFO
Rubin Eyal
CIK: 0001721411
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
